31.17
-0.58
(-1.81%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 31.04 - 31.69 |
| 52 week | 20.50 - 32.09 |
| Open | 31.69 |
| Vol / Avg. | 5.95M/5.62M |
| Mkt cap | 11.88B |
| P/E | 20.87 |
| Div/yield | - |
| EPS | 1.49 |
| Shares | 381.09M |
| Beta | 0.79 |
| Inst. own | 90% |
Events
May 24, 2013
Mylan Inc. Annual Shareholder Meeting
May 22, 2013
Mylan Inc. at UBS Global Healthcare Conference
May 15, 2013
Mylan Inc. at Bank of America Merrill Lynch Health Care Conference
May 2, 2013
Q1 2013 Mylan Inc. Earnings Conference Call
Mar 13, 2013
Mylan Inc. at Barclays Healthcare Conference
Feb 27, 2013
Q4 2012 Mylan Inc. Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 6.59% | 9.46% |
| Operating margin | 13.11% | 16.33% |
| EBITD margin | - | 32.70% |
| Return on average assets | 3.62% | 5.46% |
| Return on average equity | 13.80% | 18.76% |
| Employees | 20,000 | - |
| Carbon Disclosure Rating | - | - |
Address
1500 Corporate Drive
CANONSBURG, PA 15317
United States - Map
+1-724-5141800 (Phone)
+1-724-5141870 (Fax)
CANONSBURG, PA 15317
United States - Map
+1-724-5141800 (Phone)
+1-724-5141870 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company's product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson's disease, and a wound care product to treat diabetic foot ulcers.
Officers and directors
| Robert J. Coury | Executive Chairman of the Board | |
| Rajiv Malik | President, Director | |
| Heather Bresch | Chief Executive Officer, Director | |
| Rodney L. Piatt CPA | Vice Chairman of the Board, Lead Independent Director | |
| John D. Sheehan CPA | Executive Vice President, Chief Financial Officer, Principal Financial officer | |
| Anthony Mauro | President, North America | |
| Harry A. Korman | Chief Operating Officer, Executive Vice President | |
| Daniel C. Rizzo Jr., CPA | Senior Vice President, Chief Accounting Officer, Corporate Controller | |
| Wendy Cameron | Independent Director | |
| Robert J. Cindrich | Independent Director |
